Cabaletta Bio (CABA) Investor Presentation - Slideshow

2 Cabaletta Bio° CARTA Strategy | CABA-201 (4-1BB CD19-CAR T) expecting 1H23 IND clearance1 CAART Strategy | DSG3-CAART & MuSK-CAART clinical studies evaluating combination regimens CAART – Chimeric AutoAntibody Receptor T cells; CARTA – Chimeric Antigen Receptor T cells for Autoimmunity; IND – Investigational New Drug; SLE – Systemic lupus erythematosus; RA – Rheumatoid arthritis 5 Chimeric Antigen Receptor T cells for Autoimmunity Fully Human Anti-CD19 Targeting Domain In autoimmune diseases with a limite ...